A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Lanifibranor (Primary)
- Indications Systemic scleroderma
- Focus Proof of concept; Therapeutic Use
- Acronyms FASST
- Sponsors Inventiva Pharma
- 10 Jun 2017 Biomarkers information updated
- 03 Feb 2016 Planned number of patients changed from 105 to 132, as reported by ClinicalTrials.gov.
- 09 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.